Moderna (MRNA) Will Host Conference Call on Phase 1 Interim Analysis for mRNA Flu Vaccine on Friday, December 10

Moderna (MRNA) Reports Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update

December 10, 2021 7:00 AM EST

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first positive interim data from the Phase 1 study of the Companys quadrivalent seasonal flu vaccine candidate, mRNA-1010. In the study, mRNA-1010 successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers... More

CDC Expands Booster Recommendations To 16-and-17-year-olds - Bloomberg

December 9, 2021 2:30 PM EST

CDC Expands Booster Recommendations To 16-and-17-year-olds - Bloomberg

... More

BioNTech (BNTX) and Pfizer (PFE) Beneficiaries From Lower Omicron Vaccine Efficacy - SVB Leerink

December 9, 2021 6:28 AM EST

SVB Leerink analyst Daina Graybosch reiterated Market Perform ratings on BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE) after the companies confirmed that the protection conferred by vaccination with Comirnaty is 20-fold lower against Omicron compared to wild type... More

Moderna (MRNA) on Watch as Pfizer/BioNTech SE Three Dose Regimen Neutralizes Omicron

December 8, 2021 7:04 AM EST

Moderna (NASDAQ: MRNA) shares are on watch as rivals Pfizer/BioNTech SE said three of their vaccine doses neutralize the Omicron variant. Both use similar mRNA technology, so it could be assumed that Moderna's jab has the same impact. Shares of MRNA are down 2% in pre-open trading.

... More

Moderna (MRNA), BioNTech (BNTX) Trade to High as Study Show Reduced Protection of Current Vaccine vs Omicron

December 7, 2021 3:30 PM EST

Moderna (NASDAQ: MRNA), BioNTech SE (NASDAQ: BNTX) Trade to High as Study Show Reduced Protection of Current Vaccine vs Omicron

... More

U.S. boosters surge to all-time high on Omicron fears

December 7, 2021 1:37 PM EST

By Ahmed Aboulenein and Michael Erman

WASHINGTON (Reuters) - Americans are lining up for booster doses of COVID-19 vaccines at a record pace, with concerns about the newly-detected Omicron coronavirus variant spurring millions to get shots, the U.S. government said on Tuesday.

Just under a million people a day received booster doses of one of the three authorized vaccines last week, the highest rate since U.S. regulators gave the nod to additional shots for some adults in September, government data shows.

"In the last week, we've gotten nearly 7 million people a booster; that's a... More